Cardioconsult s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Research
At Cardioconsult s.r.o. in Stare Mesto, the clinical trial portfolio focuses on cardiovascular diseases, with studies centered on major conditions such as atrial fibrillation and atherosclerotic cardiovascular disease. The research is aimed at improving prevention and treatment strategies for serious heart-related events.
- Evaluating a new approach to preventing cardioembolic events in people with atrial fibrillation
- Studying treatment options for atherosclerotic cardiovascular disease alongside chronic kidney disease and systemic inflammation
These trials reflect a strong interest in testing therapies that may reduce the risk of stroke, embolic complications, and other major cardiovascular outcomes.
Heart and Vascular Treatment Innovation
The Kardiologicka ambulancia at this health care site is contributing to research that compares emerging therapies with established care in cardiovascular disease. The studies are designed to assess whether new treatments can better protect patients from serious events such as stroke and major adverse cardiovascular outcomes.
- Comparing a novel anticoagulation strategy with standard therapy for atrial fibrillation
- Testing whether a targeted anti-inflammatory treatment can lower cardiovascular risk in patients with ASCVD and CKD
Overall, the research at Cardioconsult s.r.o. is focused on advancing practical options for patients with complex heart and blood vessel conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cardioconsult s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Andexanet Alfa | 1 | Unknown | 2023-08-23 | 2023-08-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.